Business
Enrollment Milestone for KidneyIntelX
Enrollment Milestone for KidneyIntelX.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3159G\n Renalytix PLC\n 29 March 2022\n \n \n \n \n Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes\n \n \n \n \n \n KidneyIntelX RAPID biobank program and partners on track to reach over 30,000 biospecimens with matched electronic health records from multiple centers across the U.S.\n \n \n \n \n \n \n NEW YORK, NY and SALT LAKE CITY, UT March 29, 2022\n \n - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the proprietary Renalytix Accelerating Precision medicine In Diabetes (RAPID) biorepository is on track to exceed 4,000 unique patient biospecimens with matching, deidentified electronic health record data in 2022 through the Company's real world evidence program. RAPID, in combination with unique contracted access to large medical center patient cohorts, enables KidneyIntelXTM improvements for its bioprognosticTM methodology and therapeutic response monitoring, and supports expanded regulatory and reimbursement initiatives beginning in calendar year 2022. The RAPID biorepository was initiated in 2020 as a key part of the Renalytix real-world evidence clinical study program to accelerate the development of precision medicine products and services.\n \n \n \n \n \n With over 95% of KidneyIntelX tested patients from multiple real world evidence programs now consenting for their samples and data to be used, Renalytix expects total biospecimen access for this KidneyIntelX precision medicine platform to exceed 30,000 unique patient specimens by calendar year 2024. The KidneyIntelX RAPID biorepository is expected to continue to grow into one of the largest real-world patient biobanks incorporating current and emerging care standards for kidney disease and diabetes, including use of innovative drug treatments such as SGLT2 inhibitors, GLP1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists.\n \n \n \n \n \n \"The RAPID biorepository is an invaluable and unique source of serial patient blood and data that can accelerate product validation and provide actionable insights to help patients suffering with kidney disease and diabetes. For the KidneyIntelX platform, this will allow us to drive the development of successive versions of KidneyIntelX to address importa...